A user-friendly, open-source tool to project impact and cost of diagnostic tests for tuberculosis

Elife. 2014 Jun 4:3:e02565. doi: 10.7554/eLife.02565.

Abstract

Most models of infectious diseases, including tuberculosis (TB), do not provide results customized to local conditions. We created a dynamic transmission model to project TB incidence, TB mortality, multidrug-resistant (MDR) TB prevalence, and incremental costs over 5 years after scale-up of nine alternative diagnostic strategies. A corresponding web-based interface allows users to specify local costs and epidemiology. In settings with little capacity for up-front investment, same-day microscopy had the greatest impact on TB incidence and became cost-saving within 5 years if delivered at $10/test. With greater initial investment, population-level scale-up of Xpert MTB/RIF or microcolony-based culture often averted 10 times more TB cases than narrowly-targeted strategies, at minimal incremental long-term cost. Xpert for smear-positive TB had reasonable impact on MDR-TB incidence, but at substantial price and little impact on overall TB incidence and mortality. This user-friendly modeling framework improves decision-makers' ability to evaluate the local impact of TB diagnostic strategies.

Keywords: diagnostic techniques and procedures; economic models; epidemiology; global health; infectious disease transmission; none; tuberculosis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibiotics, Antitubercular / economics*
  • Computational Biology / methods*
  • Decision Making
  • Diagnostic Tests, Routine / economics*
  • HIV Infections / complications
  • Humans
  • Incidence
  • Internet
  • Models, Economic
  • Mycobacterium tuberculosis
  • Probability
  • Treatment Outcome
  • Tuberculosis / complications
  • Tuberculosis / diagnosis*
  • Tuberculosis / therapy
  • Tuberculosis, Multidrug-Resistant / complications
  • Tuberculosis, Multidrug-Resistant / diagnosis*
  • Tuberculosis, Multidrug-Resistant / therapy

Substances

  • Antibiotics, Antitubercular